NCT06443411

Brief Summary

Assessment and monitoring of intracranial pressure (ICP) changes are important in the management of cerebral pathologies. In the eye, ICP increase and decrease both correlate with optic neuropathies, the former because of papilledema and the latter related to glaucoma. While the relationship between ICP elevation and papilledema is well established, the relationship between low ICP and glaucoma is still poorly understood. So far, ICP monitoring is performed invasively, but this entails risks including infection, spurring the study of non-invasive alternatives. While none of currently methods in use can fully replace invasive techniques, certain measures show great potential for specific applications. In this context, monitoring the intracranial pressure changes of normal tension glaucoma may lead to a better understanding of how intracranial pressure waves vary in normal tension glaucoma. Treatment of normal tension glaucoma as a two-pressure disease needs periodic intracranial dynamic monitoring sessions for evaluation of treatment effectiveness and for needed corrections of treatment methodology. Project aim is to be able to monitor the "missing link" of intracranial dynamics of patients with normal tension glaucoma according to circadian rhythm: in the morning, during lunch and in the evening. The opportunity to monitor ICP waves non-invasively for patients with normal tension glaucoma will be implemented for the first time by using novel non-invasive intracranial pressure waves real-time monitoring system invented by KTU team in 2022 (patent applications are in the process of registration in the EU and USA).

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
156

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Apr 2024

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 22, 2024

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

May 30, 2024

Completed
6 days until next milestone

First Posted

Study publicly available on registry

June 5, 2024

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 22, 2024

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 22, 2025

Completed
Last Updated

October 9, 2024

Status Verified

May 1, 2024

Enrollment Period

8 months

First QC Date

May 30, 2024

Last Update Submit

October 7, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • A validated non-invasive ICP waves real-time monitoring technology

    Validation of non-invasive ICP waves real-time monitoring through a human eye orbit without applying external pressure to diagnose NTG with the required sensitivity and specificity to make treatment decisions.

    From 2024-04-22 till 2025-02-22

Study Arms (2)

Glaucoma group

The prospective clinical study will include at least 56 patients with NTG using non-invasive ICP waves monitoring system through a human eye orbit without applying external pressure to the eye with approximately 10 millisecond temporal resolution. It is a prospective longitudinal study of patients with normal tension glaucoma by the inclusion age from 25 to 65 years. The standard monitoring session will last 1-3 minutes. Sex: male and female. Exclusion criterion is documented neurodegenerative disorders.

Other: Monitoring of cerebral hemodynamics

Control group

100 healthy subjects using non-invasive ICP waves monitoring system through a human eye orbit without applying external pressure to the eye with approximately 10 millisecond temporal resolution.

Other: Monitoring of cerebral hemodynamics

Interventions

A specially designed pair of goggles will be put on the patient's head. The closed eyelids, along with the surrounding tissues, will be in contact with a thin, elastic, non-allergic film used to seal water filled inside the goggles. Pulse waves, including those originating from cerebrospinal fluid pulsation, will be transmitted from the eyelids to the water, where they will be detected by a pressure sensor and recorded with a laptop.

Control groupGlaucoma group

Eligibility Criteria

Age25 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study will include patients treated at the Clinic of Eye Diseases, Hospital of Lithuanian UHS.

You may qualify if:

  • years of age.
  • The patient, after reading the personal information form, confirms in writing his / her consent to participate in the study.
  • The study group includes patients with a primary open-angle normal intraocular pressure glaucoma diagnosis confirmed by an ophthalmologist (typical glaucomatous changes in the optic nerve disc and eye area, open angle of the anterior chamber, intraocular pressure in the diurnal curve with/without anti-glaucoma medication ≤ 21 mmHg) and IOP ≤ 21mmHg on study day with/without anti-glaucoma medication.
  • The control group includes healthy volunteers who do not suffer from glaucoma, acute or chronic uncompensated disease that may affect the results of the research, and according to age and anthropometric data correspond to the individuals of other research groups.

You may not qualify if:

  • Patient's refusal to participate in biomedical research.
  • Persons younger than 25 years or older than 65 years.
  • A woman who may become pregnant, be pregnant or breastfeeding.
  • The patient is allergic or sensitive to local anesthetics.
  • Suffering from an eye disease that may distort the results of the study, if so decided by the examining physician.
  • Patients who have had orbital or eye trauma.
  • Patients who have undergone any eye surgery.
  • Patients with acute or chronic, but currently aggravated, respiratory system disease.
  • Patients with uncompensated cardiovascular diseases (II-III AV block or cardiogenic shock).
  • Patients with uncompensated diabetes.
  • Neurological diseases, mental illnesses identified in the anamnesis.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Lithuanian University of Health Sciences

Kaunas, Lithuania

Location

MeSH Terms

Conditions

Low Tension Glaucoma

Condition Hierarchy (Ancestors)

GlaucomaOcular HypertensionEye DiseasesOptic Nerve Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Medical Doctor

Study Record Dates

First Submitted

May 30, 2024

First Posted

June 5, 2024

Study Start

April 22, 2024

Primary Completion

December 22, 2024

Study Completion

February 22, 2025

Last Updated

October 9, 2024

Record last verified: 2024-05

Locations